Oppenheimer Assumes Immuneering at Outperform, Announces Price Target of $25
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes Immuneering (NASDAQ:IMRX) with an Outperform rating and announces a price target of $25.
June 26, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer assumes Immuneering with an Outperform rating and sets a price target of $25.
Oppenheimer's Outperform rating and $25 price target for Immuneering indicate a positive outlook for the stock. This news is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100